Oncología Traslacional
ONCTRAS
Hospital Arnau de Vilanova
Valencia, EspañaPublicacións en colaboración con investigadores/as de Hospital Arnau de Vilanova (8)
2017
-
18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial
Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441
-
Critically short telomeres and toxicity of chemotherapy in early breast cancer
Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2015
-
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer
Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137
2012
-
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis
Annals of Oncology, Vol. 23, Núm. 5, pp. 1130-1137
-
Progress against solid tumors in danger: The metastatic breast cancer example
Journal of Clinical Oncology
2010
2009
-
Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 11, Núm. 6, pp. 363-375